Pseudotyped GFP HPV39

Name: Pseudotyped GFP HPV39
SKU: PSVG-HPV39
Rating: 5 (1 reviews)

COA

SDS

Datasheet

Summary

Product Overview

HPV39 Pseudovirus are used to test the ability of serum and antibodies to neutralize the infectivity of HPV39. HPV39 Pseudovirus are produced in 293FT cells using three separate plasmids, encoding the HPV L1 protein, the HPV L2 protein, and a reporter gene. HPV39 Pseudovirus display antigenically correct L1 and L2 protein pseudotyped on replication-incompetent virus particles. Pseudovirus are capable of a single round of infection and carry a plasmid that expresses GFP optical reporter gene upon infection.

Nature

Virus

Application Notes

The recommended amount of pseudovirus per well can be found in the Certificate of Analysis for each lot of pseudovirus.

Storage

Store at -80°C. Multiple freeze/thaw cycles not recommended.
When using the virus, transfer the virus from the -80 ° C refrigerator and melt it in an ice bath.

Ship

Frozen on dry ice

Citations

Have you cited PSVG-HPV39 in a publication? Let us know and earn a reward for your research.

Background

Long-term studies have found that persistent HPV infection significantly increases the development of cervical cancer. More than 200 different types of HPV have been identified, with HPV39 classified as a high-risk HPV. Persistent infection with high-risk types of HPV can lead to precancerous lesions in several parts of the body, including the vagina, vulva, cervix, head and neck, and anus. HPV prevalence varies widely depending on geography, age, cervical screening programmes, etc. HPV16 is the most prevalent oncogenic genotype worldwide, followed by HPV18. A person can be infected with many different types of HPV at the same time or multiple times, due to the fact that the immune response to natural infections is relatively weak and specific to only the particular type of HPV they have been infected with.

The course of HPV infection cervical cancer can be divided into four stages, including infection, persistent infection, cervical precancerous lesions, and cervical cancer. 80 % of women will be infected with HPV in their lifetime, and most HPV infections do not cause symptoms or disease and are only transient. Persistent high-risk HPV infection is a necessary prerequisite for the development of cervical cancer. Most women with the virus clear HPV rapidly within 6-12 months of detection, and the longer a high-risk HPV infection persists in a detectable state, the higher the risk of causing severe cervical intraepithelial neoplasia (CIN3). It is commonly believed that it takes 10 to 20 years of continuous HPV infection to develop cervical cancer.

Steps in the development of cervical cancer caused by HPV Figure 1. Conceptual model of HPV infection leading to cervical cancer
(Source: Schiffman M, et al. 2016)

Vaccines are considered the most effective and safe way to prevent HPV infection. The HPV prophylactic vaccines currently in use can be categorized into three types: bivalent vaccine against HPV16 and HPV18, quadrivalent vaccine against HPV6, 11, 16 and 18, and nonavalent vaccine against HPV6, 11, 16, 18, 31, 33, 45, 52 and 58. Although current HPV vaccines are expected to reduce the incidence of HPV-induced cervical cancer, they provide protection against only a small number of HPV types and do not cover all HPV types. Secondly, the possibility exists that non-vaccine HPV genotypes could replace HPV vaccine genotypes and become causative agents of cervical precancerous lesions and cancers in vaccinated populations.

Alternative Names

Pseudotyped GFP Human papillomavirus 39
Pseudotyped GFP Human papillomavirus type 39

References

1. Schiffman M, et al. Carcinogenic human papillomavirus infection. Nat Rev Dis Primers. 2016 Dec 1;2:16086.
2. Szymonowicz KA, et al. Biological and clinical aspects of HPV-related cancers. Cancer Biol Med. 2020 Nov 15;17(4):864-878.

Documents

pdf COA

pdf SDS

pdf Datasheet

Pseudotyped Reporter Viruses

HPV Reagents for Vaccine Research and Immunoassay Development

QA & Reviews

Q & A

Ask a Question

Q: Can you please help me understand the safety risk of a pseudo-virus and how it might compare to the safety level of a non-replicative lentivirus or retrovirus?

A: Because PsV are capable of transferring foreign DNA, they should be handled using full biosafety level 2 precautions. It is important to note that the promiscuity of packaging by L1 and L2 can lead to generation of PsV with encapsidated fragments of cellular DNA, possibly including SV40 large tumor antigen, adenovirus oncogenes, or unknown oncogenes present in 293TT cells. Mature PsV can be inactivated by 70% ethanol, but, like many other types of non-enveloped virus particles, they are resistant to a wide spectrum of physical insults, including various detergents and proteases, prolonged heating at 56°C, 50 mM EDTA, and sodium chloride up to at least 1.5 M (unpublished results). PsV are probably also resistant to dessication. High-titer PsV should never be harvested using tip sonication, which can create potentially dangerous aerosols.

Customer Reviews